Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korean Analysts Retain Optimism For Daewoong Pharmaceutical On Early Pipeline and In-licensing

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Daewoong Pharmaceutical has beefed up its product lineup and increased R&D investment for high-growth therapeutic areas, which has brightened the company's outlook in the eyes of some Korean analysts despite stronger generics competition in 2011
Advertisement

Related Content

Daewoong Pharmaceutical To In-license Almirall's COPD drug Eklira In Korea
Korea's Tightened Regulatory Grip Drops Daewoong and Dong-A Rx Sales In Q2, But OTC Sales Strong
Korea's Tightened Regulatory Grip Drops Daewoong and Dong-A Rx Sales In Q2, But OTC Sales Strong
Merck Turns Again To Daewoong For Co-promotion In South Korea
Merck Turns Again To Daewoong For Co-promotion In South Korea
2011 Preview: Will Korean Pharmas Follow Japanese Pharmas Lead To Survive Harsh Environment At Home?
Green Cross And MNC-Linked Daewoong Stand Out In Korea's Sluggish 3rd Quarter
Green Cross And MNC-Linked Daewoong Stand Out In Korea's Sluggish 3rd Quarter
Advertisement
UsernamePublicRestriction

Register

SC077114

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel